Open Access

Proteasome inhibitors in glioblastoma (Review)

  • Authors:
    • Wen-Juan Huang
    • Wei-Wei Chen
    • Xia Zhang
  • View Affiliations

  • Published online on: Wednesday, January 11, 2017
  • Pages:1058-1062 DOI: 10.3892/ol.2017.5585
0

Abstract

Glioblastomas (GBM) are the tumors originating from the star shaped supportive cells in brain known as astrocytes. These tumors are highly cancerous as they have the ability to proliferate very quickly. New therapeutic strategies are being developed worldwide to fight against deadly GBM, which has median survival time of just 14 months. Proteasome inhibition is an upcoming strategy for GBM. Proteasome inhibition has shown promising results in cancers such as myeloma. However, in the recent past this form of therapy has also shown positive results in brain tumors in the form of elevated apoptosis. We searched the electronic database PubMed for pre-clinical as well as clinical controlled trials reporting importance of proteasome inhibitors during GBM. It was observed clearly that this approach is evolving and has been observed to be promising therapeutic avenue against GBM. Thus, the present review aims to enlighten the present views on use of proteasome inhibition strategy in the case of GBM.

Related Articles

Journal Cover

March 2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

2015 Impact Factor: 1.482
Ranked #97/211 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Huang, W., Chen, W., & Zhang, X. (2017). Proteasome inhibitors in glioblastoma (Review). Oncology Letters, 13, 1058-1062. http://dx.doi.org/10.3892/ol.2017.5585
MLA
Huang, W., Chen, W., Zhang, X."Proteasome inhibitors in glioblastoma (Review)". Oncology Letters 13.3 (2017): 1058-1062.
Chicago
Huang, W., Chen, W., Zhang, X."Proteasome inhibitors in glioblastoma (Review)". Oncology Letters 13, no. 3 (2017): 1058-1062. http://dx.doi.org/10.3892/ol.2017.5585